Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy.
(2010) In Diabetes Care 33(4). p.730-732- Abstract
- Objective - To determine if the dipeptidyl peptidase 4 inhibitor vildagliptin more effectively than the sulfonylurea glimepiride inhibits glucagon levels during meal. Research design and methods - Glucagon responses to a standard meal were measured at baseline and study endpoint (mean 1.8 years) in a trial evaluating add-on therapy to metformin with vildagliptin 50 mg bid compared to glimepiride up to 6 mg qd in type 2 diabetes (baseline HbA1c 7.3+/-0.6%). Results - HbA(1c) and prandial glucose AUC(0-2h) were reduced similarly in both groups, while prandial insulin AUC(0-2h) increased to a greater extent by glimepiride. Prandial glucagon AUC(0-2h) (baseline 66.6+/-2.3 pmol.h/l) decreased by 3.4+/-1.6 pmol.h/l by vildagliptin group (n=137)... (More)
- Objective - To determine if the dipeptidyl peptidase 4 inhibitor vildagliptin more effectively than the sulfonylurea glimepiride inhibits glucagon levels during meal. Research design and methods - Glucagon responses to a standard meal were measured at baseline and study endpoint (mean 1.8 years) in a trial evaluating add-on therapy to metformin with vildagliptin 50 mg bid compared to glimepiride up to 6 mg qd in type 2 diabetes (baseline HbA1c 7.3+/-0.6%). Results - HbA(1c) and prandial glucose AUC(0-2h) were reduced similarly in both groups, while prandial insulin AUC(0-2h) increased to a greater extent by glimepiride. Prandial glucagon AUC(0-2h) (baseline 66.6+/-2.3 pmol.h/l) decreased by 3.4+/-1.6 pmol.h/l by vildagliptin group (n=137) and increased by 3.8+/-1.7 pmolh/l by glimepiride group (n=121). The between-group difference was 7.3+/-2.1 pmol.h/l (p<0.001). Conclusion - Vildagliptin therapy but not glimepiride improves post-prandial alpha-cell function, which persists for at least 2 years. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1541165
- author
- Ahrén, Bo LU ; Foley, James E ; Ferrannini, E ; Matthews, David R ; Zinman, Bernard ; Dejager, Sylvie and Fonseca, Vivian A
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Diabetes Care
- volume
- 33
- issue
- 4
- pages
- 730 - 732
- publisher
- American Diabetes Association
- external identifiers
-
- wos:000276793200007
- pmid:20067974
- scopus:77953055922
- pmid:20067974
- ISSN
- 1935-5548
- DOI
- 10.2337/dc09-1867
- language
- English
- LU publication?
- yes
- id
- 12d8375e-ac75-4018-a5ba-66769ff226b2 (old id 1541165)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20067974?dopt=Abstract
- date added to LUP
- 2016-04-01 13:29:25
- date last changed
- 2024-01-09 14:25:07
@article{12d8375e-ac75-4018-a5ba-66769ff226b2,
abstract = {{Objective - To determine if the dipeptidyl peptidase 4 inhibitor vildagliptin more effectively than the sulfonylurea glimepiride inhibits glucagon levels during meal. Research design and methods - Glucagon responses to a standard meal were measured at baseline and study endpoint (mean 1.8 years) in a trial evaluating add-on therapy to metformin with vildagliptin 50 mg bid compared to glimepiride up to 6 mg qd in type 2 diabetes (baseline HbA1c 7.3+/-0.6%). Results - HbA(1c) and prandial glucose AUC(0-2h) were reduced similarly in both groups, while prandial insulin AUC(0-2h) increased to a greater extent by glimepiride. Prandial glucagon AUC(0-2h) (baseline 66.6+/-2.3 pmol.h/l) decreased by 3.4+/-1.6 pmol.h/l by vildagliptin group (n=137) and increased by 3.8+/-1.7 pmolh/l by glimepiride group (n=121). The between-group difference was 7.3+/-2.1 pmol.h/l (p<0.001). Conclusion - Vildagliptin therapy but not glimepiride improves post-prandial alpha-cell function, which persists for at least 2 years.}},
author = {{Ahrén, Bo and Foley, James E and Ferrannini, E and Matthews, David R and Zinman, Bernard and Dejager, Sylvie and Fonseca, Vivian A}},
issn = {{1935-5548}},
language = {{eng}},
number = {{4}},
pages = {{730--732}},
publisher = {{American Diabetes Association}},
series = {{Diabetes Care}},
title = {{Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy.}},
url = {{http://dx.doi.org/10.2337/dc09-1867}},
doi = {{10.2337/dc09-1867}},
volume = {{33}},
year = {{2010}},
}